| Bioactivity | Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection[1][2]. | ||||||
| In Vivo | Apstatin (1 mg/kg; i.v.; 5 min before ischaemia) TFA 可减少急性心肌缺血模型中的心肌梗塞面积 (IS)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | ||||||
| Formula | C25H34F3N5O7 | ||||||
| Molar Mass | 573.56 | ||||||
| Appearance | 固体 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
| Reference | [1]. Wolfrum S, et al. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol. 2001 Sep;134(2):370-4. [2]. Maggiora LL, et al. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42(13):2394-402. |